Expertise in
15
conditions

Dr. Jason Chesney

Oncology
Uofl Health James Graham Brown Cancer Center
529 S Jackson St, 
Louisville, KY 
Accepting New Patients
Expertise in
15
conditions
Uofl Health James Graham Brown Cancer Center
529 S Jackson St, 
Louisville, KY 

Overview

Jason Chesney is an Oncologist practicing medicine in Louisville, Kentucky.

Dr. Chesney is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Melanoma, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Pleuropulmonary Blastoma.

He is actively involved in clinical research, co-authoring 79 peer reviewed articles and participating in 7 clinical trials. Dr. Chesney is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in KY

Hospital Affiliations

University Of Louisville Hospital
Norton Hospitals, Inc
UOFL HEALTH - JEWISH HOSPITAL And Mary & Elizabeth Hospital
Uofl Health - Shelbyville Hospital
Baptist Health Louisville

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Michigan Health
  • HMO
  • INSURANCE PLAN
  • MEDICARE MAPD
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Uofl Health James Graham Brown Cancer Center
529 S Jackson St, Louisville, KY 40202
Other Locations
Uofl Health-Brown Cancer Center
529 S Jackson St, Louisville, KY 40202
Uofl Health-Brown Cancer Center-Blood Cancer, Cellular Therapeutics And Transplant Program
2401 Terra Crossing Blvd Ste 200, Louisville, KY 40245

Additional Areas of Focus

Dr. Chesney has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients With Metastatic Melanoma
A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients With Metastatic Melanoma
Enrollment Status: Completed
Publish Date: March 25, 2026
Intervention Type: Biological
Study Drug: Lifileucel
Study Phase: Phase 2
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2026
Intervention Type: Biological
Study Drugs: RP1, Nivolumab
Study Phase: Phase 2
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2025
Intervention Type: Drug
Study Drugs: TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel
Study Phase: Phase 1
A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects With Advanced Melanoma (DELTA-1)
A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects With Advanced Melanoma (DELTA-1)
Enrollment Status: Terminated
Publish Date: April 16, 2024
Intervention Type: Biological
Study Drug: ITIL-168
Study Phase: Phase 2
Extended Interval Port Flushes: A Phase II Clinical Trial
Extended Interval Port Flushes: A Phase II Clinical Trial
Enrollment Status: Completed
Publish Date: July 19, 2021
Intervention Type: Other
Study Phase: Phase 2
View 6 Less Clinical Trials

79 Total Publications

Planning, Reporting, and Selective Disclosure of Quality-of-Life End Points in Phase III Genitourinary Cancer Trials.
Planning, Reporting, and Selective Disclosure of Quality-of-Life End Points in Phase III Genitourinary Cancer Trials.
Journal: JCO oncology advances
Published: August 28, 2026
Similar Doctors
Expertise in
27
conditions
Expertise in
27
conditions
Referral may be required

Norton Cancer Institute - Downtown

676 South Floyd Street, 
Louisville, KY 
 (0.4 miles away)
502-629-2500
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Hamm is an Oncologist practicing medicine in Louisville, Kentucky. He has been practicing medicine for over 44 years. Dr. Hamm is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Pancreatic Cancer, and Pleuropulmonary Blastoma. Dr. Hamm is board certified in American Board Of Internal Medicine, Medical Oncology - 1989 and American Board Of Internal Medicine, Internal Medicine - 1985. Dr. Hamm is currently accepting new patients.

Expertise in
35
conditions
Expertise in
35
conditions
Referral may be required

Norton Cancer Institute Radiation Center - Downtown

676 South Floyd Street, 
Louisville, KY 
 (0.4 miles away)
502-629-4555
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Aaron Spalding is an Oncologist practicing medicine in Louisville, Kentucky. Dr. Spalding is highly rated in 35 conditions, according to our data. His clinical expertise encompasses Posterior Fossa Tumor, Metastatic Brain Tumor, Primitive Neuroectodermal Tumor (PNET), Rhizotomy, and Microvascular Decompression. Dr. Spalding is board certified in American Board Of Radiology, Radiation Oncology - 2009. Dr. Spalding is currently accepting new patients.

Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Norton Cancer Institute Brownsboro

4955 Norton Healthcare Blvd, 
Louisville, KY 
 (10.2 miles away)
502-394-6350
Languages Spoken:
English, Italian
See accepted insurances
Accepting New Patients

Renato La Rocca is an Oncologist practicing medicine in Louisville, Kentucky. Dr. La Rocca is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Embryonal Tumor with Multilayered Rosettes, Neuroepithelioma, and Atypical Teratoid Rhabdoid Tumor (ATRT). Dr. La Rocca is currently accepting new patients.

Frequently Asked Questions about Dr. Jason Chesney

How do I make an appointment with Dr. Jason Chesney?

You can book an appointment with Dr. Jason Chesney by calling their office at 502-562-4673. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jason Chesney a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jason Chesney is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jason Chesney specialize in?

While Dr. Jason Chesney is a Oncology, they have specific expertise in Melanoma, Lung Cancer, and Non-Small Cell Lung Cancer (NSCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Jason Chesney participate in research or clinical trials?

Yes. Dr. Jason Chesney has published 79 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Jason Chesney's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jason Chesney accept my insurance?

Dr. Jason Chesney accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 502-562-4673 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chesney's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 71 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile